PT1246814E - Compostos e metodos para a modulacao de receptores de estrgenio - Google Patents

Compostos e metodos para a modulacao de receptores de estrgenio

Info

Publication number: PT1246814E
Authority: PT; Portugal
Prior art keywords: compounds; methods; disclosed; beta; same
Prior art date: 1999-12-30

Application number

PT00990966T

Other languages

English (en)

Inventor

Shripad S Bhagwat

Sak Khammungkhune

Jeffrey A Mckie

Original Assignee

Signal Pharm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-30

Filing date

2000-12-29

Publication date

2005-07-29

2000-01-27 Priority claimed from US09/492,939 external-priority patent/US6291456B1/en

2000-07-06 Priority claimed from US09/611,156 external-priority patent/US6331562B1/en

2000-12-29 Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc

2005-07-29 Publication of PT1246814E publication Critical patent/PT1246814E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Obesity (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PT00990966T 1999-12-30 2000-12-29 Compostos e metodos para a modulacao de receptores de estrgenio PT1246814E (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US47577699A	1999-12-30	1999-12-30
US09/492,939 US6291456B1 (en)	1998-12-30	2000-01-27	Compounds and methods for modulation of estrogen receptors
US09/611,156 US6331562B1 (en)	1998-12-30	2000-07-06	Compounds and methods for modulation of estrogen receptors

Publications (1)

Publication Number	Publication Date
PT1246814E true PT1246814E (pt)	2005-07-29

Family

ID=27413348

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT00990966T PT1246814E (pt)	1999-12-30	2000-12-29	Compostos e metodos para a modulacao de receptores de estrgenio

Country Status (14)

Country	Link
EP (1)	EP1246814B1 (pt)
JP (1)	JP2003519219A (pt)
KR (1)	KR20020075388A (pt)
CN (1)	CN1281598C (pt)
AT (1)	ATE289300T1 (pt)
AU (1)	AU781282B2 (pt)
CA (1)	CA2396059A1 (pt)
DE (1)	DE60018215T2 (pt)
DK (1)	DK1246814T3 (pt)
ES (1)	ES2238034T3 (pt)
HK (1)	HK1058521A1 (pt)
IL (1)	IL150463A0 (pt)
PT (1)	PT1246814E (pt)
WO (1)	WO2001049673A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CO5271709A1 (es) *	2000-01-12	2003-04-30	Pfizer Prod Inc	Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
EP1177787A3 (en) *	2000-07-28	2003-09-10	Pfizer Products Inc.	Use of an estrogen agonist/antagonist for treating cataracts
EP1281710A1 (en) *	2001-08-03	2003-02-05	CHIESI FARMACEUTICI S.p.A.	2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
US7148252B2 (en) *	2001-10-03	2006-12-12	Signal Pharmaceuticals, Llc	Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
EP1448544B1 (en)	2001-11-19	2007-05-16	Eli Lilly And Company	Substituted benzopyrans as selective estrogen receptor-beta agonists
US7524866B2 (en)	2001-11-29	2009-04-28	Gtx, Inc.	Prevention and treatment of androgen—deprivation induced osteoporosis
AU2005202072B2 (en) *	2001-11-29	2008-10-23	Gtx, Inc.	Prevention and treatment of androgen-deprivation induced conditions
ES2305350T3 (es) *	2001-11-29	2008-11-01	Gtx, Inc.	Prevencion y tratamiento de la osteoporosis inducida por la privacion de androgenos.
NZ536291A (en) *	2002-04-19	2006-09-29	Signal Pharm Inc	Benzopyranone compounds, compositions thereof, and methods of treatment therewith
US7091235B2 (en)	2002-10-15	2006-08-15	Signal Pharmaceuticals, Llc	Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
US7674783B2 (en) *	2002-11-22	2010-03-09	Dimera Inc.	Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
US7279499B2 (en)	2003-04-21	2007-10-09	Eli Lilly And Company	Substituted benzopyrans as selective estrogen receptor-beta agonists
US7442812B2 (en)	2003-04-21	2008-10-28	Eli Lilly And Company	Substituted benzopyrans as selective estrogen receptor-beta agonists
US7098340B2 (en) *	2003-05-14	2006-08-29	Warner Lambert Company Llc	Benzyl sulfonamide derivatives
BRPI0414386A (pt) *	2003-09-15	2006-11-21	Signal Pharm Llc	composto, métodos para fabricação do mesmo, para tratamento ou prevenção de uma doença, para ativação da função de er em uma célula óssea, para inibição de função de er em uma célula, para inibição da expressão de il-6, para inibição do crescimento de uma célula neoplásica expressando er, para prevenção de espermatogenese, para prevenção de um efeito reprodutivo adverso associados com exposição a uma falta de equilìbrio hormonal natural ou quìmica ambiental, e, composição
EP1846386A2 (en) *	2005-01-21	2007-10-24	Janssen Pharmaceutica N.V.	Novel coumarin derivatives as ion channel openers
CA2656067C (en)	2006-06-23	2014-08-12	Radius Health, Inc.	Treatment of vasomotor symptoms with selective estrogen receptor modulators
MX342898B (es)	2010-05-12	2016-10-18	Radius Health Inc *	Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
JP5965909B2 (ja)	2010-09-28	2016-08-10	ラジウスヘルス，インコーポレイテッド	選択的アンドロゲン受容体モジュレーター
US9421264B2 (en)	2014-03-28	2016-08-23	Duke University	Method of treating cancer using selective estrogen receptor modulators
CA2943611A1 (en)	2014-03-28	2015-10-01	Duke University	Method of treating cancer using selective estrogen receptor modulators
CN105801543B (zh) *	2016-04-18	2019-08-02	中国药科大学	4-芳香胺-香豆素衍生物及其制备方法和医药用途
CN105801544A (zh) *	2016-04-18	2016-07-27	中国药科大学	3-芳基-4-芳香胺-香豆素衍生物及其制备方法和医药用途
SG11201811225RA (en)	2016-06-22	2019-01-30	Radius Health Inc	Ar+ breast cancer treatment methods
CN106492204A (zh) *	2016-12-27	2017-03-15	郑州郑先医药科技有限公司	一种治疗白内障的药物组合物
CN106727637A (zh) *	2016-12-27	2017-05-31	郑州郑先医药科技有限公司	一种治疗白内障的西药组合物及其用途
JP7481115B2 (ja)	2017-01-05	2024-05-10	ラジウスファーマシューティカルズ，インコーポレイテッド	Ｒａｄ１９０１－２ｈｃｌの多形性形態

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5883118A (en) *	1996-01-11	1999-03-16	Nova Nordisk A/S	Prostatic carcinoma
US5726202A (en) *	1996-01-11	1998-03-10	Novo Nordisk A/S	Benign prostatic hypertrophy
HUP9902683A3 (en) *	1996-01-11	2001-08-28	Novo Nordisk As	Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
ATE248157T1 (de) *	1998-12-30	2003-09-15	Signal Pharm Inc	Verbindungen und verfahren zur modulation von estrogen rezeptoren

2000
- 2000-12-29 KR KR1020027008569A patent/KR20020075388A/ko active IP Right Grant
- 2000-12-29 JP JP2001550213A patent/JP2003519219A/ja active Pending
- 2000-12-29 DE DE60018215T patent/DE60018215T2/de not_active Expired - Fee Related
- 2000-12-29 WO PCT/US2000/035671 patent/WO2001049673A2/en active IP Right Grant
- 2000-12-29 EP EP00990966A patent/EP1246814B1/en not_active Expired - Lifetime
- 2000-12-29 IL IL15046300A patent/IL150463A0/xx unknown
- 2000-12-29 AT AT00990966T patent/ATE289300T1/de not_active IP Right Cessation
- 2000-12-29 AU AU30771/01A patent/AU781282B2/en not_active Ceased
- 2000-12-29 PT PT00990966T patent/PT1246814E/pt unknown
- 2000-12-29 ES ES00990966T patent/ES2238034T3/es not_active Expired - Lifetime
- 2000-12-29 CN CNB008192227A patent/CN1281598C/zh not_active Expired - Fee Related
- 2000-12-29 DK DK00990966T patent/DK1246814T3/da active
- 2000-12-29 CA CA002396059A patent/CA2396059A1/en not_active Abandoned
2004
- 2004-02-20 HK HK04101233A patent/HK1058521A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP1246814B1 (en)	2005-02-16
WO2001049673A2 (en)	2001-07-12
EP1246814A2 (en)	2002-10-09
ES2238034T3 (es)	2005-08-16
CA2396059A1 (en)	2001-07-12
AU3077101A (en)	2001-07-16
IL150463A0 (en)	2002-12-01
AU781282B2 (en)	2005-05-12
CN1437591A (zh)	2003-08-20
HK1058521A1 (en)	2004-05-21
KR20020075388A (ko)	2002-10-04
CN1281598C (zh)	2006-10-25
DE60018215T2 (de)	2006-02-09
ATE289300T1 (de)	2005-03-15
DE60018215D1 (de)	2005-03-24
JP2003519219A (ja)	2003-06-17
DK1246814T3 (da)	2005-05-30
WO2001049673A3 (en)	2001-12-06

Publication	Publication Date	Title
PT1246814E (pt)	2005-07-29	Compostos e metodos para a modulacao de receptores de estrgenio
WO2000055137A8 (en)	2001-07-05	Compounds and methods for modulation of estrogen receptors
PT1140889E (pt)	2004-01-30	Compostos e metodos para modulacao de receptores de estrogenio
MY115784A (en)	2003-09-30	Estrogen agonists/antagonists
MY112949A (en)	2001-10-31	Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia
CR6478A (es)	2004-02-02	Moduladores del receptor glucocorticoide
CY1115231T1 (el)	2017-01-04	Εκλεκτικος ρυθμιστης οιστρογονικου υποδοχεα σε συνδυασμο με δεϋδροεπιανδροστερονη (dhea) ή αναλογα
ATE397125T1 (de)	2008-06-15	Geschwollene stärke-latex-zusammensetzungen zur anwendung bei der papierherstellung
NO20020913D0 (no)	2002-02-25	Androgenreseptor-modulatorforbindelser og fremgangsmåter
Castoria et al.	2004	Rapid signalling pathway activation by androgens in epithelial and stromal cells
WO2007016385A3 (en)	2007-04-12	Use of substituted 5-amino-1h-pyrrole-2-carbonitrile derivatives as progesterone receptor modulators
PE20040678A1 (es)	2004-10-06	Moduladores de los receptores selectivos de estrogenos
ES2180845T3 (es)	2003-02-16	Composiciones de silicona dispersables.
DE59911879D1 (de)	2005-05-12	Verwendung von biogenen estrogensulfamaten zur hormonsubstitutionstherapie
PT1273572E (pt)	2005-03-31	Piperazinas substituidas com tiofeno uteis no tratamento da hiperplasia prostatica benigna
Jensen et al.	2004	A two-site model for antiestrogen action
LT2002031A (en)	2003-02-25	Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
NO20020260D0 (no)	2002-01-17	11<beta>-aryl-17,17-spirotiolansubstituerte steroider
Meyers	1984	The role of hormone receptors in estrogen activity is questionable
Charnock-Jones et al.	1998	Vascular endothelial growth factor and corpus luteum angiogenesis
MY137604A (en)	2009-02-27	Benzopyranone compounds, compositions thereof, and methods of treatment therewith
Boyde	1984	Stereographic visual aids
BR0214334A (pt)	2004-09-14	Método para prover uma composição de base tópica para uso na preparação de uma composição cosmética, recipiente cosmético re-selável, e, composição anidra
TWI227146B (en)	2005-02-01	Orthopedic material and usage method thereof
Ishii et al.	2009	A NEW THERAPEUTIC STRATEGY FOR TARGETING TUMOR STROMA IN HORMONE-REFRACTORY PROSTATE CANCER CELL GROWTH UNDER ANDROGEN ABLATION THERAPY: 1331